Phenotypic and Transcriptomic Description of Megakaryocytes in Sickle Cell Patient
About this study
Sickle cell disease is the most common inherited blood disorder in the world. Chronic hemolysis induces platelet activation and chronic inflammation. Platelets and megakaryocyte, as medullar platelets precursors, are known to play a role in innate immunity. Little is known about the role of megakaryocytes at basal state and during acute complication in sickle cell disease patients. The aim of this study is to evaluate the role of megakaryocytes in sickle cell disease.
- Condition
- Sickle Cell Disease (SCD)
- Sponsor
- University Hospital, Toulouse
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 5
- Minimum age: 18 years
- Study condition: Sickle Cell Disease (SCD)
- Sickle cell disease SS or S-béta° thalassemia
- Patient at steady state since at least 1 year or at steady state (without crisis), or during vaso-occlusive crisis or during acute chest syndrome
- Age \> 18 years old
Exclusion 4
- Patient objects to take part in the study Hematologic disorder (leukemia, myeloma, myelodysplasic syndrome, myeloproliferative syndrome)
- Immune thrombocytopenia, Immunosuppressive or anti-inflammatory (biotherapies, corticosteroids, non steroidal anti-inflammatories drugs) Page 12 sur 23
- Anti-platelets agents
- Red blood cell exchange or transfusion \< 3 months
Where
1 site, 1 recruiting
CHU de Toulouse
Toulouse, France, France
Contact
-
Pierre COUGOUL, MD
0531156265 cougoul.pierre@iuct-oncopole.fr
Potential match only. Final eligibility is determined by the study team.